Benson Don M, Elder Patrick J, Lin Thomas S, Blum William, Penza Sam, Avalos Belinda, Copelan Edward, Farag Sherif S
Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling-Loving Hall, Columbus, OH 43210, USA.
Leuk Res. 2007 Aug;31(8):1069-75. doi: 10.1016/j.leukres.2006.09.021. Epub 2006 Oct 30.
High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) has improved response rates and survival for patients with multiple myeloma (MM). We report a single-institution experience using two conditioning regimens, busulfan, cyclophosphamide, and etoposide (BCV) or high-dose melphalan (HDM). Between July 1992 and August 2003, 110 patients with MM (median age=56.1) underwent HDC with ASCT using either BCV (n=62) or HDM (n=48) in sequential cohorts as the preparative regimen. Overall response rates, progression-free survival, and median overall survival were similar. BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM.
大剂量化疗（HDC）联合自体干细胞移植（ASCT）提高了多发性骨髓瘤（MM）患者的缓解率和生存率。我们报告了在单一机构使用两种预处理方案的经验，即白消安、环磷酰胺和依托泊苷（BCV）或大剂量美法仑（HDM）。1992年7月至2003年8月，110例MM患者（中位年龄=56.1岁）接受了HDC联合ASCT，在连续队列中分别使用BCV（n=62）或HDM（n=48）作为预处理方案。总体缓解率、无进展生存期和中位总生存期相似。在MM患者中，BCV和HDM作为自体干细胞移植前的预处理方案，具有相似的长期疗效和相似的毒性特征。
